Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

351 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Toward the harmonization of immune monitoring in clinical trials: quo vadis?
Britten CM, Janetzki S, van der Burg SH, Gouttefangeas C, Hoos A. Britten CM, et al. Among authors: van der burg sh. Cancer Immunol Immunother. 2008 Mar;57(3):285-8. doi: 10.1007/s00262-007-0379-z. Epub 2007 Aug 25. Cancer Immunol Immunother. 2008. PMID: 17721782 Free PMC article. No abstract available.
Dendritic cells in colorectal cancer correlate with other tumor-infiltrating immune cells.
Dadabayev AR, Sandel MH, Menon AG, Morreau H, Melief CJ, Offringa R, van der Burg SH, Janssen-van Rhijn C, Ensink NG, Tollenaar RA, van de Velde CJ, Kuppen PJ. Dadabayev AR, et al. Among authors: van der burg sh, van de velde cj. Cancer Immunol Immunother. 2004 Nov;53(11):978-86. doi: 10.1007/s00262-004-0548-2. Epub 2004 Jun 17. Cancer Immunol Immunother. 2004. PMID: 15197496 Free PMC article.
The CIMT-monitoring panel: a two-step approach to harmonize the enumeration of antigen-specific CD8+ T lymphocytes by structural and functional assays.
Britten CM, Gouttefangeas C, Welters MJ, Pawelec G, Koch S, Ottensmeier C, Mander A, Walter S, Paschen A, Müller-Berghaus J, Haas I, Mackensen A, Køllgaard T, thor Straten P, Schmitt M, Giannopoulos K, Maier R, Veelken H, Bertinetti C, Konur A, Huber C, Stevanović S, Wölfel T, van der Burg SH. Britten CM, et al. Among authors: van der burg sh. Cancer Immunol Immunother. 2008 Mar;57(3):289-302. doi: 10.1007/s00262-007-0378-0. Epub 2007 Aug 25. Cancer Immunol Immunother. 2008. PMID: 17721783 Free PMC article.
Chirality of TLR-2 ligand Pam3CysSK4 in fully synthetic peptide conjugates critically influences the induction of specific CD8+ T-cells.
Khan S, Weterings JJ, Britten CM, de Jong AR, Graafland D, Melief CJ, van der Burg SH, van der Marel G, Overkleeft HS, Filippov DV, Ossendorp F. Khan S, et al. Among authors: van der burg sh, van der marel g. Mol Immunol. 2009 Mar;46(6):1084-91. doi: 10.1016/j.molimm.2008.10.006. Epub 2008 Nov 22. Mol Immunol. 2009. PMID: 19027958
Performance of serum-supplemented and serum-free media in IFNgamma Elispot Assays for human T cells.
Janetzki S, Price L, Britten CM, van der Burg SH, Caterini J, Currier JR, Ferrari G, Gouttefangeas C, Hayes P, Kaempgen E, Lennerz V, Nihlmark K, Souza V, Hoos A. Janetzki S, et al. Among authors: van der burg sh. Cancer Immunol Immunother. 2010 Apr;59(4):609-18. doi: 10.1007/s00262-009-0788-2. Epub 2009 Nov 6. Cancer Immunol Immunother. 2010. PMID: 19894047 Free PMC article.
Response definition criteria for ELISPOT assays revisited.
Moodie Z, Price L, Gouttefangeas C, Mander A, Janetzki S, Löwer M, Welters MJ, Ottensmeier C, van der Burg SH, Britten CM. Moodie Z, et al. Among authors: van der burg sh. Cancer Immunol Immunother. 2010 Oct;59(10):1489-501. doi: 10.1007/s00262-010-0875-4. Epub 2010 Jun 15. Cancer Immunol Immunother. 2010. PMID: 20549207 Free PMC article.
Minimal information about T cell assays: the process of reaching the community of T cell immunologists in cancer and beyond.
Britten CM, Janetzki S, van der Burg SH, Huber C, Kalos M, Levitsky HI, Maecker HT, Melief CJ, O'Donnell-Tormey J, Odunsi K, Old LJ, Pawelec G, Roep BO, Romero P, Hoos A, Davis MM. Britten CM, et al. Among authors: van der burg sh. Cancer Immunol Immunother. 2011 Jan;60(1):15-22. doi: 10.1007/s00262-010-0940-z. Epub 2010 Nov 16. Cancer Immunol Immunother. 2011. PMID: 21080166 Free PMC article.
Successful treatment of metastatic melanoma by adoptive transfer of blood-derived polyclonal tumor-specific CD4+ and CD8+ T cells in combination with low-dose interferon-alpha.
Verdegaal EM, Visser M, Ramwadhdoebé TH, van der Minne CE, van Steijn JA, Kapiteijn E, Haanen JB, van der Burg SH, Nortier JW, Osanto S. Verdegaal EM, et al. Among authors: van steijn ja, van der burg sh, van der minne ce. Cancer Immunol Immunother. 2011 Jul;60(7):953-63. doi: 10.1007/s00262-011-1004-8. Epub 2011 Mar 24. Cancer Immunol Immunother. 2011. PMID: 21431917 Free PMC article. Clinical Trial.
Recommendations from the iSBTc-SITC/FDA/NCI Workshop on Immunotherapy Biomarkers.
Butterfield LH, Palucka AK, Britten CM, Dhodapkar MV, Håkansson L, Janetzki S, Kawakami Y, Kleen TO, Lee PP, Maccalli C, Maecker HT, Maino VC, Maio M, Malyguine A, Masucci G, Pawelec G, Potter DM, Rivoltini L, Salazar LG, Schendel DJ, Slingluff CL Jr, Song W, Stroncek DF, Tahara H, Thurin M, Trinchieri G, van Der Burg SH, Whiteside TL, Wigginton JM, Marincola F, Khleif S, Fox BA, Disis ML. Butterfield LH, et al. Among authors: van der burg sh. Clin Cancer Res. 2011 May 15;17(10):3064-76. doi: 10.1158/1078-0432.CCR-10-2234. Epub 2011 May 10. Clin Cancer Res. 2011. PMID: 21558394 Free PMC article. Review.
351 results